NfL-Guided Neuroprotection Therapy is a biomarker-driven treatment strategy that uses neurofilament light chain (NfL) levels as a primary efficacy readout to guide neuroprotective interventions in neurodegenerative diseases.
NfL is a sensitive marker of axonal injury that can be measured in cerebrospinal fluid (CSF) and blood. Elevations in NfL correlate with disease progression in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
The therapy targets multiple pathways to reduce axonal damage and lower NfL levels:
- Axonal stability enhancement - Promoting cytoskeletal integrity
- Mitochondrial protection - Reducing energy failure-induced axonal degeneration
- Neuroinflammation reduction - Dampening immune-mediated axonal injury
- Synaptic protection - Preventing synaptic loss
| Biomarker |
Target |
Measurement Method |
Expected Change |
| NfL (plasma/CSF) |
Lower than baseline |
Simoa assay |
30-50% reduction |
| NfL (serum) |
Lower than baseline |
Simoa assay |
30-50% reduction |
| Neurogranin |
Stabilization |
CSF ELISA |
Prevention of rise |
| SNAP-25 |
Stabilization |
CSF ELISA |
Prevention of rise |
¶ Therapeutic Candidates
- Cytosine arabinoside - Microtubule stabilizer
- Rablyrazole - Neurotrophic factor inducer
- Mitochondrial protectants - CoQ10 analogs
- Anti-NfL antibodies - Passive immunization to clear NfL aggregates
- Growth factors - BDNF, GDNF delivery
- Amiloride - ENaC blocker with neuroprotective properties
- Trihexyphenidyl - MT stabilizer
- Elevated baseline NfL (>50 pg/mL in CSF)
- Diagnosis of AD, PD, or ALS
- Disease duration <5 years
- Primary: Change in plasma NfL at 12 months
- Secondary: Cognitive scores, motor function, brain atrophy
- Phase 2: Dose-finding with NfL as biomarker
- Phase 3: Confirmatory with clinical endpoints
- Baseline variability - NfL levels vary significantly between patients
- Disease specificity - NfL elevation is not disease-specific
- Therapeutic window - Optimal timing for intervention unclear
- Biomarker access - Repeat CSF sampling invasive
- Development of blood-based NfL assays for easier monitoring
- Combination therapy guided by multi-biomarker panels
- Personalized medicine based on NfL trajectory